Kennedy disease results from a hemizygous expansion of a CAG trinucleotide repeat in exon 1 of the androgen receptor gene (AR), located on the X chromosome (per GeneReviews). Normal AR alleles contain 34 or fewer CAG repeats; full-penetrance alleles contain 38 or more CAG repeats. The ClinGen Expert Panel has classified the AR-SBMA disease association as DEFINITIVE. The disease follows X-linked inheritance; males who inherit the expanded allele are hemizygous and affected, while heterozygous females are typically unaffected carriers. The expanded CAG repeat produces a mutant androgen receptor protein with a toxic gain-of-function mechanism, leading to progressive degeneration of lower motor neurons in the spinal cord and brainstem. Per GeneReviews, genotype-phenotype correlations establish an inverse relationship between CAG repeat number and age of symptom onset, though CAG repeat length accounts for only approximately 60% of observed clinical variability. Alleles in the 35-37 CAG range carry uncertain or reduced penetrance and require interpretation within clinical and family context.

Per GeneReviews, SBMA is a diagnostic consideration in males presenting with progressive spinal lower motor neuron disease including limb weakness, muscle cramps, and decreased reflexes, combined with bulbar lower motor neuron signs including tongue fasciculations, dysarthria, and dysphagia, in the absence of upper motor neuron findings. Signs of androgen insensitivity, particularly gynecomastia, and family history consistent with X-linked inheritance further support clinical suspicion. The diagnosis is established by molecular genetic testing demonstrating a hemizygous CAG trinucleotide repeat expansion of 38 or more in the AR gene; targeted CAG repeat size analysis by fragment length analysis of PCR-amplified products identifies the expansion in 100% of affected males (per GeneReviews). Alleles of 36-37 repeats carry reduced penetrance and are interpreted within clinical context. Per GeneReviews, SBMA is most frequently confused with amyotrophic lateral sclerosis; approximately 1 in 25 individuals initially diagnosed with ALS is ultimately found to have SBMA, with clinical differentiation relying on identification of androgen insensitivity signs and the absence of upper motor neuron involvement.

No FDA-approved pharmacotherapy for Kennedy disease has been identified in this packet. Per GeneReviews, management of SBMA involves multidisciplinary supportive care. Physical medicine, rehabilitation, physical therapy, and occupational therapy address mobility and activities of daily living, with provision of adaptive devices including ankle-foot braces, walkers, and wheelchairs as the disease progresses. Speech-language therapy addresses dysarthria; feeding evaluations address dysphagia risk, with diet modifications and gastrostomy tube placement for severely affected individuals. Per GeneReviews, clinical trials of high-dose testosterone and anti-androgen therapy including leuprorelin have been undertaken; these trials did not establish clinical efficacy for the neurological manifestations of SBMA. Three agents carry FDA orphan drug designation for spinal and bulbar muscular atrophy: geranylgeranylacetone, insulin-like growth factor-1, and a curcumin-based compound.

Per GeneReviews, the majority of individuals with Kennedy disease have a normal life expectancy and are unlikely to die from direct complications of motor neuron disease. The disease follows a slowly progressive course; approximately one third of affected males require a wheelchair about 20 years after symptom onset. The main life-threatening complication is aspiration pneumonia or ventilatory failure from bulbar and respiratory muscle weakness, which likely affects only a minority of individuals. In one cohort of 223 individuals, 15 deaths occurred at a mean age of 65 years. Genotype-phenotype analysis shows an inverse correlation between CAG repeat length and age of onset, accounting for approximately 60% of observed variability (per GeneReviews). Metabolic complications including hyperlipidemia and insulin resistance may predispose to coronary artery disease with aging, particularly given declining physical activity from progressive neuromuscular disease. Sensory neuropathy from dorsal root ganglion degeneration contributes to fall risk and potential injury.

Active clinical research in Kennedy disease includes biomarker studies, natural history registries, and pharmacological trials. The NIH National Institute of Neurological Disorders and Stroke sponsors a clinical, molecular, and imaging biomarker study in SBMA (NCT04944940, recruiting, 2021-2027). An international SBMA project coordinated by Fondazione IRCCS Istituto Neurologico Carlo Besta (NCT07443449) is active through December 2026. Phase 2 pharmacological trials include an investigation of mexiletine hydrochloride for SBMA (NCT06862596, recruiting, through 2027) and a placebo-controlled study of clenbuterol in SBMA (NCT06169046, recruiting, through 2027). The Sanford Rare Disease Patient Registry (NCT01793168) enrolls individuals with Kennedy disease among other rare conditions. The Kennedy's Disease Association (kennedysdisease.org) operates an active patient registry and is the primary patient advocacy organization documented in this packet. The research landscape comprises 51 classified publications, with basic science and preclinical work as the dominant type, and active gene therapy and trial-related publications.